NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Myelodysplastic syndrome (MDS) is a pre-leukemic condition with a high risk of progressing to acute myeloid leukemia (AML).
• Constitutive activation of the NF-kappaB signaling pathway has been observed in MDS and AML.
• NF-kappaB plays a critical role in regulating apoptosis and cell survival.

Purpose of the Study:

• To investigate the role of NF-kappaB activation in the pathogenesis of MDS.
• To determine the effect of NF-kappaB inhibition on MDS cell apoptosis and survival.
• To explore the potential of NF-kappaB as a therapeutic target in MDS.

Main Methods:

• Utilized the P39 MDS/AML cell line and primary bone marrow cells from high-risk MDS patients.
• Employed small interfering RNAs (siRNAs) targeting p65 and chemical inhibitors like bortezomib to inhibit NF-kappaB.
• Assessed apoptosis, mitochondrial transmembrane potential, and the release of death effectors (cytochrome c, endonuclease G, AIF).
• Analyzed nuclear translocation of the p65 subunit in CD34+ and CD33+ cells.

Main Results:

• NF-kappaB inhibition in the P39 cell line led to apoptosis via mitochondrial pathways and release of death effectors.
• Bone marrow cells from high-risk MDS patients exhibited constitutive NF-kappaB activation, with p65 nuclear translocation correlating with disease progression.
• NF-kappaB activation was restricted to cells with MDS-associated cytogenetic abnormalities.
• NF-kappaB inhibition induced rapid apoptosis in MDS patient-derived cells.

Conclusions:

• Constitutive NF-kappaB activation contributes to the suppression of apoptosis in differentiating MDS cells, promoting malignant transformation.
• NF-kappaB inhibition demonstrates potential as a therapeutic strategy for MDS by inducing apoptosis in MDS stem cells.